Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||MultiTAA-specific T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MultiTAA-specific T cells||TAA-CTL|TAA-T|TAA-specific CTLs||MultiTAA-specific T cells are T-lymphocytes that have been treated with dendritic cells exposed to a cocktail of tumor-associated antigens (TAAs) such as WT1, PRAME, NY-ESO1, MAGEA4 and Survivin, which have potential antitumor activity against tumors expressing TAAs (Blood (2015) 126 (23): 186; Blood (2017) 130 (Supplement 1): 164).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02789228||Phase I||MultiTAA-specific T cells||Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)||Recruiting|
|NCT03192462||Phase Ib/II||MultiTAA-specific T cells||TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS)||Active, not recruiting|
|NCT03093350||Phase II||MultiTAA-specific T cells||TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC)||Active, not recruiting|
|NCT03652545||Phase I||MultiTAA-specific T cells||Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND)||Recruiting|
|NCT01333046||Phase I||MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells||Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL)||Recruiting|
|NCT02475707||Phase I||MultiTAA-specific T cells||Administration of Donor MultiTAA-Specific T Cells for ALL (STELLA)||Recruiting|
|NCT02291848||Phase I||MultiTAA-specific T cells||Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM)||Recruiting|
|NCT02203903||Phase I||MultiTAA-specific T cells||Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)||Recruiting|
|NCT02494167||Phase I||MultiTAA-specific T cells||Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)||Recruiting|